Similar articles

• [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].

  Marcos Sánchez F, Albo Castaño MI, Casallo Blanco S. Marcos Sánchez F, et al. Rev Clin Esp. 2007 Mar;207(3):150-1; author reply 151-2. Rev Clin Esp. 2007. PMID: 17397643 Spanish. No abstract available.
• Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.

  Jiménez-Méndez R, Castañeda-Hernández G. Jiménez-Méndez R, et al. Ann Hepatol. 2010;9 Suppl:61-4. Ann Hepatol. 2010. PMID: 20713998
• Pegylated interferon and ribavirin in real life: efficacy versus effectiveness.

  de Mattos AZ, de Almeida PR, Tovo CV, de Mattos AA. de Mattos AZ, et al. Hepatology. 2010 Nov;52(5):1867. doi: 10.1002/hep.23824. Hepatology. 2010. PMID: 20726033 No abstract available.
• [Treatment strategies of acute and chronic hepatitis C].

  Gładysz A, Inglot M. Gładysz A, et al. Przegl Epidemiol. 2002;56 Suppl 5:10-5. Przegl Epidemiol. 2002. PMID: 15553066 Review. Polish.
• Hepatitis C (chronic).

  Mohsen A, Norris S. Mohsen A, et al. Clin Evid. 2006 Jun;(15):1061-72. Clin Evid. 2006. PMID: 16973044 Review. No abstract available.